<DOC>
	<DOCNO>NCT02338336</DOCNO>
	<brief_summary>To evaluate drug safety efficacy patient treat Nowarta110 determine therapeutic activity Plantar Warts - Clinical Tolerance - Clinical Recovery - Evaluate Safety</brief_summary>
	<brief_title>A Phase I/II Double-blind Safety Efficacy Evaluation Nowarta110 Patients With Plantar Warts</brief_title>
	<detailed_description>Plantar Warts occur sol ( plantar surface foot ) severely debilitate patient even normal walking . The severity magnitude wart vary , cause much pain discomfort age group . Nowarta 110 evaluate therapy plantar wart cause HPV virus , ( HPV infection ) . Clinical experience total 124 patient receive Nowarta 110 5 week treatment multiple clinic overseas demonstrate potential Nowarta110 absolutely side effect .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Foot Diseases</mesh_term>
	<criteria>Patients refractory recurrent Plantar Warts . No wart treatment last 12 week Healthy male nonpregnant , nonlactating female age â‰¥ 18 year great If female childbearing potential , use acceptable form birth control study Provide write informed consent ( HIPAA consent/authorization , applicable Concurrent medical disorder disease make implementation interpretation protocol result difficult unsafe Female subject breastfeed plan become pregnant Patients history allergy silver fruit Subjects clinically significant unstable medical disorder , life threaten disease , current malignancy Subjects History Alcohol abuse drug abuse within 2 year prior Randomization Subjects treat investigational drug investigational device within period 30 day prior study enrollment Concomitant Medications : wart therapy prohibit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>